Modern immunological criteria for a stratification of risk groups for precursor B cell acute lymphoblastic leukemia in children

封面

如何引用文章

全文:

详细

Background. Modern therapy programs allow achieving high survival rates in children with acute lymphoblastic leukemia (ALL). However, there is a group of patients in whom a relapse occurs, which makes it necessary to search for optimal tools for monitoring remission and the earliest detection of ALL relapse. According to clinical and immunological studies, assessment of minimal residual disease (MRD) levels is one of the leading criteria for response to treatment and can be the basis for risk-stratified therapy.

Aim. Assessment of MRD levels on the 15th day of induction as the main parameter for stratification of patients into prognostic risk groups and the impact of MOB levels on patient survival.

Materials and methods. The study included 117 children with a newly diagnosed precursor B-cell ALL. All patients were given an induction course according to the BFM ALL IC 2009 protocol.

MRD levels were determined by flow cytometry.

Results. Given the MRD –based stratification, a “truly” standard risk group was identified, the survival rate of which reached 100%.

Conclusions. The use of MRD as the main tool for the risk of adapted therapy made it possible to improve survival in patients of the standard risk group, as well as to optimize therapy for high and medium risk groups in the future.

作者简介

Meri Shervashidze

Blokhin National Medical Research Center of Oncology

编辑信件的主要联系方式.
Email: shervashidze85@gmail.com
ORCID iD: 0000-0002-8350-4153

Res. Officer

俄罗斯联邦, Moscow

Timur Valiev

Blokhin National Medical Research Center of Oncology

Email: timurvaliev@mail.ru
ORCID iD: 0000-0002-1469-2365

D. Sci. (Med.)

俄罗斯联邦, Moscow

Natalia Batmanova

Blokhin National Medical Research Center of Oncology

Email: timurvaliev@mail.ru
ORCID iD: 0000-0002-5728-2243

Cand. Sci. (Med.)

俄罗斯联邦, Moscow

Nikolai Tupitsyn

Blokhin National Medical Research Center of Oncology

Email: timurvaliev@mail.ru
ORCID iD: 0000-0003-3966-128X

D. Sci. (Med.)

俄罗斯联邦, Moscow

Irina Serebryakova

Blokhin National Medical Research Center of Oncology

Email: timurvaliev@mail.ru
ORCID iD: 0000-0002-8389-4737

Cand. Sci. (Med.)

俄罗斯联邦, Moscow

参考

  1. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2013 году (заболеваемость и смертность). М., 2015. [Kaprin A.D., Starinskii V.V., Petrova G.V. Malignant neoplasms in Russia in 2013 (morbidity and mortality). Moscow, 2015 (in Russian).]
  2. Garcia-Manero G, Yang H, Kuang S-Q et al. Epigenetics of Acute Lymphocytic Leukemia. Semin Hematol 2009; 46 (1): 24–32.
  3. Бойченко Э.Г., Румянцева Ю.В., Пономарева Н.И. и др. Сравнительный анализ результатов химиотерапии острого лимфобластного лейкоза у детей по программам ALL-MB-2002 и сoall-st. Petersburg-92. Онкогематология. 2010; 2. [Boichenko E.G., Rumiantseva Iu.V., Ponomareva N.I. et al. Sravnitel’nyi analiz rezul’tatov khimioterapii ostrogo limfoblastnogo leikoza u detei po programmam ALL-MB-2002 i soall-st. Petersburg-92. Onkogematologiia. 2010; 2 (in Russian).]
  4. Dejean D, Krahn H, Giacomini M et al. Health Technology Assessment at Health Quality Ontario. Ont Health Technol Assess Ser 2016; 16 (16): 1–22.
  5. Volejnikova J, Jarosova M, Pospisilova D et al. Treatment and prognosis of childhood acute lymphoblastic leukemia on protocols ALL-BFM 90, 95 and ALL IC-BFM 2002: a retrospective single-center study from Olomouc, Czech Republic. Neoplasma 2016; 63 (3): 456–61.
  6. Савва Н.Н., Красько О.В., Белевцев М.В. и др. Прогностическое значение минимальной остаточной болезни для безрецидивной выживаемости детей с острым лимфобластным лейкозом на протоколе ОЛЛ-МБ-2002 (однофакторный и многофакторный анализ). Онкогематология. 2009; 2. [Savva N.N., Kras’ko O.V., Belevtsev M.V. et al. Prognosticheskoe znachenie minimal’noi ostatochnoi bolezni dlia bezretsidivnoi vyzhivaemosti detei s ostrym limfoblastnym leikozom na protokole OLL-MB-2002 (odnofaktornyi i mnogofaktornyi analiz). Onkogematologiia. 2009; 2 (in Russian).]
  7. Bassan R, Spinelli O, Oldani E et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 2009; 113 (18): 4153–62.
  8. Brüggemann M, Schrauder A, Raff T et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008. Leukemia 2010; 24 (3): 521–35.
  9. Schrappe M, Valsecchi MG, Bartram CR et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood 2011; 118 (8): 2077–84.
  10. Fronkova E, Mejstrikova E, Avigad S et al. Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing? Leukemia 2008; 22 (5): 989–97.
  11. An F-Y, Zhang S-H, Kong L-J et al. Clinical Significance of Minimal Residual Disease in Risk Stratification and Prognosis of Childhood B-lineage Acute Lymphoblastic Leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2017; 25 (3): 729–35.
  12. Attarbaschi A, Mann G, Panzer-Grümayer R et al. Minimal Residual Disease Values Discriminate Between Low and High Relapse Risk in Children With B-Cell Precursor Acute Lymphoblastic Leukemia and an Intrachromosomal Amplification of Chromosome 21: The Austrian and German Acute Lymphoblastic Leukemia Berlin-Frankfurt-Münster (ALL-BFM) Trials. J Clin Oncol 2008; 26 (18): 3046–50.
  13. Pui C-H, Pei D, Coustan-Smith E et al. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncol 2015; 16 (4): 465–74.
  14. Тупицын Н.Н., Гривцова Л.Ю., Купрышина Н.А. Проточная цитометрия в онкогематологии. Ч. I. Основы и нововведения в диагностике острых лейкозов. Клин. онкогематология. 2012; 5 (1). [Tupitsyn N.N., Grivtsova L.Iu., Kupryshina N.A. Protochnaia tsitometriia v onkogematologii. Ch. I. Osnovy i novovvedeniia v diagnostike ostrykh leikozov. Klin. onkogematologiia. 2012; 5 (1) (in Russian).]
  15. Bruggemann M. Standardized mrd monitoring in european all trials. Ann Hematol 2013; 92: S33–S36.
  16. Campana D. Minimal residual disease monitoring in childhood acute lymphoblastic leukemia. Curr Opin Hematol 2012; 19 (4): 313–8.
  17. Зуховицкая Е.В., Фиясь А.Т. Острые лимфобластные лейкозы. Журн. Гродненского государственного медицинского университета. 2015; 3 (51). [Zukhovitskaia E.V., Fiias’ A.T. Ostrye limfoblastnye leikozy. Zhurn. Grodnenskogo gosudarstvennogo meditsinskogo universiteta. 2015; 3 (51) (in Russian).]
  18. Менткевич Г.Л., Маякова С.А. Лейкозы у детей. Практическая медицина. М., 2009. [Mentkevich G.L., Maiakova S.A. Leukemia in children. Practical medicine. Moscow, 2009 (in Russian).]
  19. Alvarnas JC, Brown PA, Aoun P et al. Acute lymphoblastic leukemia. J Natl Compr Cancer Netw JNCCN 2012; 10 (7): 858–914.
  20. Безнос О.А., Гривцова Л.Ю., Попа А.В. и др. Определение минимальной остаточной болезни при В-линейных острых лимфобластных лейкозах с использованием подходов Euroflow. Клин. Онкогематология. 2017; 10 (2): 158–68. [Beznos O.A., Grivtsova L.Yu., Popa A.V. et al. Evaluation of Minimal Residual Disease in B-lIneage acute lymphoblastic leukemia using euro flow approaches. Clin Oncohematology. 2017; 10 (2): 158–68 (in Russian)]

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Consilium Medicum, 2019

Creative Commons License
此作品已接受知识共享署名-非商业性使用 4.0国际许可协议的许可。
 


##common.cookie##